3 Immunohistochemistry of interleukin-1 (IL-1) in the dorsal root ganglion (DRG) and spinal cord (SC) at (A) 5 min (representative value of phase 1) and (B) 35 min (representative value of phase 2) Graph (bottom) represents the number of immunostained cells in the DRG and SC (mean SD)
Dysregulated lipid metabolism, altered lactate levels, and impaired energy metabolism are key factors that may exacerbate ROS levels
PT-141 Peptide Injections PT-141 peptide injections support sexual desire and arousal by activating pathways in the brain rather than affecting hormone levels or blood flow
For gut healing specifically, taking it orally or intraperitoneally puts the peptide in direct contact with the gut lining
No Established Human Protocols Human dosing, cycling, and combination protocols have not been established for 5-Amino-1MQ
REDEFINE Trial Headlines Trial REDEFINE 1 Phase 3 Duration 68 weeks Population (N) 3,417 adults with obesity or overweight + 1 comorbidity, without T2D Key Result 20.4% mean weight change vs 3.0% placebo (treatment-policy)
